Specialty and emerging peptides Newer compounds like SS-31 , 5-amino-1MQ , tesofensine , and kisspeptin may have less well-established storage data compared to legacy compounds
10.1021/acsami.6b00371 ACS Appl Mater Interfaces
Fitness should matter more to people using these products for weight loss, and this underscores the need for more education on the importance of preserving fitness while losing weight
Wegrzyn, L
Those who continued the medication maintained or continued to lose weight, while those who stopped regained much of the weight lost, underscoring the need for long-term therapy.23 Longer-term outcomes were assessed in STEP 5, which extended treatment to 104 weeks and demonstrated sustained weight loss of approximately 15%.24 In East Asian populations, STEP 6 showed similar results, with participants achieving an average 12% to 13% weight loss over 68 weeks.25 STEP 7, a 44-week trial including participants from China, Hong Kong, Brazil, and South Korea, found that those on semaglutide lost an average of 12.1% of their body weight compared with 3.6% with placebo.26 Lastly, STEP 8 compared semaglutide with liraglutide and showed greater efficacy with semaglutide (15.8% vs 6.4% weight loss), as well as better tolerability and more convenient weekly dosing.27 Taken together, the STEP trials show that semaglutide consistently results in clinically meaningful weight loss across various populations and treatment conditions
